

Randomised crossover trial to determine whether a beta blocker and an Angiotensin Converting Enzyme (ACE) inhibitor have independent effects in lowering blood pressure

Submission date 02/03/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 16/05/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 03/05/2011	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr David Wald

Contact details

Wolfson Institute of Preventive Medicine
Charterhouse Square
London
United Kingdom
EC1 M6BQ
d.s.wald@qmul.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Acronym

CTBP (Combination Therapy Blood Pressure) Trial

Study objectives

Randomised, crossover trial to determine whether a beta blocker and an ACE inhibitor have independent effects in lowering blood pressure.

Ethics approval required

Old ethics approval format

Ethics approval(s)

East London Local Research Ethics Committee on 04/05/2004 (ref: DAI/MY/P304040)

Study design

Randomised, placebo-controlled, crossover trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cardiovascular disease

Interventions

All participants received each of the following interventions:

1. Atenolol 25 mg
2. Lisinopril 5 mg
3. Atenolol 25 mg + lisinopril 5 mg
4. Placebo

sequentially in a random sequence.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Systolic and diastolic blood pressure.

Secondary outcome measures

Adverse effects.

Overall study start date

14/04/2004

Completion date

14/12/2004

Eligibility**Key inclusion criteria**

1. Men or women over age 40
2. Blood pressure over 100/60 mmHg

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

60

Key exclusion criteria

1. Peripheral vascular disease
2. Asthma
3. Atrial Fibrillation (AF)

Date of first enrolment

14/04/2004

Date of final enrolment

14/12/2004

Locations

Countries of recruitment

United Kingdom

Study participating centre

Wolfson Institute of Preventive Medicine

London

United Kingdom

EC1 M6BQ

Sponsor information

Organisation

Queen Mary University of London (UK)

Sponsor details

Charterhouse Square

London

United Kingdom

EC1 M6BQ

gerry.leonard@bartsandthelondon.nhs.uk

Sponsor type

University/education

ROR

<https://ror.org/026zzn846>

Funder(s)

Funder type

Other

Funder Name

Investigator-funded (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2008		Yes	No